GET DAILY SIGNALSIQVIA Holdings (IQV) Delivers Q3 2026 Earnings Beat with Revenue and EPS Gains
Key Takeaways
- IQVIA reported third-quarter 2026 revenue of $4,428 million, up 8% year over year and above the consensus estimate of roughly $4.36 billion.
- Adjusted diluted earnings per share (EPS) came in at $3.34, topping analyst expectations and exceeding the high end of management's guidance.
- Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) rose 8.7% to $1,032 million, reflecting continued operating leverage.
- The company slightly raised its full-year 2026 outlook for both revenue and adjusted diluted EPS, signaling confidence in ongoing demand.
- Research & Development Solutions revenue grew 8.7% year over year, while Commercial Solutions revenue rose 6.9%, supported by its strongest clinical bookings quarter since 2022.
- For more detail on IQV's Major News, Today's Price Move, Price Targets, and Forecasts, explore the dedicated pages for this ticker.
- To discover AI-driven trading strategies, explore Trending AI Robots.
Earnings Context and Why It Matters
IQV is a leading global provider of clinical research services, commercial insights, and healthcare intelligence to the life sciences industry. Its quarterly results are closely watched as a barometer for pharmaceutical and biotechnology research-and-development (R&D) spending, a key driver of the broader healthcare outsourcing market. Heading into the third quarter, investors were focused on whether demand indicators such as clinical trial starts, request-for-proposal (RFP) flow, and contract bookings would continue to strengthen. A stabilizing funding environment and growing adoption of AI-enabled offerings have supported the company's momentum. This report matters because it offers a read on both near-term revenue conversion and the durability of the industry's recovery. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
For the third quarter ended September 30, 2026, IQV reported revenue of $4,428 million, an 8% increase from $4,100 million in the prior-year period and above Wall Street's consensus estimate of about $4.36 billion. Adjusted diluted EPS reached $3.34, exceeding analyst estimates that clustered around $3.28 and beating the prior year's adjusted result of roughly $3.00 per share. On a GAAP (Generally Accepted Accounting Principles) basis, diluted EPS was $2.10.
Segment performance was broad-based. Research & Development Solutions revenue grew 8.7% year over year, while Commercial Solutions revenue rose 6.9%. Adjusted EBITDA increased 8.7% to $1,032 million. Management highlighted the strongest clinical quarterly bookings since 2022 and accelerating organic growth, noting that more than 400 AI agents have been deployed to date. Free cash flow for the quarter was $667 million.
Market Reaction and Investor Sentiment
IQV entered the report with positive momentum, with shares up more than 20% year to date ahead of the announcement. The combination of a top-line beat, an adjusted EPS beat, and a modest upward revision to full-year guidance reinforced the narrative of a strengthening demand environment. Key factors shaping investor interpretation include the improvement in clinical bookings, the acceleration in organic growth across both segments, and continued traction in AI-powered solutions. Areas of attention on the downside include the year-over-year decline in the free cash flow margin and ongoing integration and talent-retention considerations as the company scales its reorganized structure.
Forward Outlook and Key Factors to Monitor
Looking ahead, IQV slightly lifted its full-year 2026 guidance, pointing to revenue near $17.43 billion at the midpoint and adjusted diluted EPS near $12.95 at the midpoint. This suggests management expects demand momentum to persist into the fourth quarter, supported by favorable indicators such as biotech funding, RFP flow, clinical trial starts, regulatory approvals, and outsourcing trends.
Investors should monitor whether the strength in clinical bookings translates into sustained revenue conversion, particularly as contracted backlog converts over coming quarters. The pace of AI-enabled solution adoption remains another key theme, given management's emphasis on deploying AI agents across commercial and clinical offerings.
Margin trends and cash conversion also warrant attention. While adjusted EBITDA grew solidly, the free cash flow margin dipped year over year, and continued investment in technology and organizational restructuring could pressure near-term profitability. Balance-sheet dynamics, including leverage levels and the pace of share repurchases, will remain part of the conversation as the company balances growth investments with shareholder returns.
Using AI Tools in My Research Process
In my analysis of earnings reports like this one, I frequently rely on Tickeron’s AI Screener to quickly filter stocks by fundamentals, technical patterns, and industry benchmarks. It allows me to compare IQV against peers in healthcare services and spot emerging trends that might not be obvious from the numbers alone. This tool has become a regular part of how I build context around quarterly results and refine my watchlists.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for IQV turns positive, indicating new upward trend
IQV saw its Momentum Indicator move above the 0 level on October 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 76 similar instances where the indicator turned positive. In 52 of the 76 cases, the stock moved higher in the following days. The odds of a move higher are at 68%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for IQV just turned positive on October 21, 2026. Looking at past instances where IQV's MACD turned positive, the stock continued to rise in 24 of 42 cases over the following month. The odds of a continued upward trend are 57%.
Following a +0.99% 3-day Advance, the price is estimated to grow further. Considering data from situations where IQV advanced for three days, in 187 of 302 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
The Aroon Indicator entered an Uptrend today. In 120 of 222 cases where IQV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 54%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IQV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
IQV broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 6 (best 1 - 100 worst), indicating outstanding price growth. IQV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 31 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 43 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.298) is normal, around the industry mean (65.624). P/E Ratio (33.695) is within average values for comparable stocks, (2.414). Projected Growth (PEG Ratio) (0.985) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.693) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 84 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IQV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock better than average.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of biopharmaceutical development services and commercial outsourcing services
Industry MedicalSpecialties
Advertisement